NCT04572451
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma treatment 1 recruiting NCT02690545
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL No drug interventions treatment 1 / 2 recruiting NCT05147493
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment treatment 2 not_yet_recruiting NCT04556071
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer treatment 2 unknown_status NCT03911388
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors treatment 1 active_not_recruiting NCT00102609
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma treatment 1 completed NCT01995942
Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial No drug interventions Not Available Not Available unknown_status NCT05241873
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations treatment 1 / 2 active_not_recruiting NCT03744676
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) treatment 2 completed NCT04862780
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC treatment 1 / 2 active_not_recruiting NCT01234480
Intended Use Study of the BD SurePath Plus™ Pap No drug interventions diagnostic Not Available terminated NCT06175780
Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT00878189
A Trial In Patients With Advanced Cancer And Leukemia treatment 1 completed NCT04310592
Natural Killer Cell (CYNK-001) Infusions in Adults With AML treatment 1 recruiting NCT04222972
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) treatment 3 active_not_recruiting NCT05797246
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) treatment 2 recruiting NCT04697446
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC No drug interventions Not Available Not Available unknown_status NCT01579253
Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients No drug interventions Not Available Not Available unknown_status NCT04249947
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) treatment 1 active_not_recruiting NCT02543645
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer treatment 1 terminated NCT04124198
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma treatment Not Available recruiting NCT02663297
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas No drug interventions treatment 1 active_not_recruiting NCT05298683
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor treatment 2 not_yet_recruiting NCT02386111
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma treatment 1 terminated NCT01009593
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) treatment 3 terminated NCT05252078
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients treatment 2 recruiting NCT02897778
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors treatment 1 completed NCT06001788
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia treatment 1 recruiting NCT03037385
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors treatment 1 / 2 completed NCT05155215
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma treatment 1 / 2 unknown_status NCT01556815
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma No drug interventions treatment 2 unknown_status NCT04312737
Evaluation of in Vitro Devices on Self-collected Vaginal Swab and Urine Sample for Testing of Human Papilloma Virus No drug interventions Not Available Not Available completed NCT05770037
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers treatment 2 / 3 recruiting NCT04566952
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer treatment 2 unknown_status NCT02909452
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors treatment 1 completed NCT06271252
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study treatment 1 recruiting NCT01037049
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks No drug interventions other 2 unknown_status NCT05186558
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL treatment 2 not_yet_recruiting NCT02158858
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis treatment 1 / 2 active_not_recruiting NCT03722186
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies No drug interventions treatment 1 suspended NCT04807166
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer treatment 2 active_not_recruiting NCT02005965
Low Rectal Cancer Study (MERCURY II) No drug interventions Not Available Not Available unknown_status NCT04949282
Spanish Series of Patients Treated With the Radionuclide Lutetium177 Not Available Not Available recruiting NCT05770544
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. treatment 2 / 3 recruiting NCT05440240
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture No drug interventions treatment 4 recruiting NCT05160168
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) treatment 1 / 2 terminated NCT05153408
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC treatment 1 terminated NCT05592743
Vorasidenib Expanded Access Program Not Available Not Available available NCT03495921
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide treatment 3 terminated NCT05770102
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition treatment 2 / 3 recruiting NCT04309084
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma treatment 1 active_not_recruiting NCT02798406
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects treatment 2 completed NCT03373019
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 unknown_status NCT05935748
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) treatment 2 recruiting